Back to top

Analyst Blog

DaVita, the dialysis unit of DaVita Healthcare Partners Inc. (DVA - Analyst Report), has joined forces with the Yangpu District healthcare authorities of Shanghai, China to provide quality care to dialysis patients in the district at an affordable price. DaVita is one of the premier kidney care providers in the U.S. for services in the country and abroad.

With approval from the government and the health bureau of the Yangpu district, DaVita is collaborating with the Shanghai Yangpu Antu Hospital. The two entities will form a Renal Dialysis Technology Collaboration Base at the hospital. Through the high-end renal care and dialysis network at the Yangpu Antu Hospital, Davita will receive a research platform that will allow it to provide cost-effective patient care in China.

As per the terms of the collaboration, DaVita will provide consultation services to the hospital. These pertain to advanced management processes for the hospital’s renal outpatient visits and dialysis treatments. Concurrently, the alliance aims to improve clinical outcomes at the hospital by enhancing technology, increasing the number of dialysis provision units utilizing DaVita’s expertise in this arena and at the same time minimizing medical expenditure.

Previously, DaVita forayed into the Chinese market through a joint venture with a biotechnology developer in northeastern China – 3sBio Inc. As per sources, worldwide prevalence of chronic kidney diseases is on the rise and China comes in at the upper end of the list of countries that have a high prevalence of patients suffering from kidney disorders. Thus, China is in need of cost-effective, high-quality of patient kidney care. These deals give DaVita the opportunity to strengthen its foothold in China and drive growth.

DaVita is strengthening its operations and also its existence in the international markets through partnerships for some time now. Among its other partnership endeavors, the association with Myriad RBM in Jun 2013 and Arizona Integrated Physicians (AIP) in Sep 2013 are worth mentioning. Myriad RBM is a wholly owned subsidiary of molecular diagnostic company, Myriad Genetics Inc. (MYGN - Analyst Report) while AIP is a physician owned West-Valley based organization. While the deal with Myriad is aimed at performing a protein biomarker discovery research to introduce innovative diagnostic tests in the dialysis market, the association with AIP was to widen its presence in Arizona.

DaVita Healthcare currently carries a Zacks Rank #3 (Hold). Among other healthcare service providers, Addus HomeCare Corporation (ADUS - Snapshot Report) with a Zacks Rank #1 (Strong Buy) and HEALTHSOUTH Corp. (HLS - Snapshot Report) with a Zacks Rank #2 (Buy) appear impressive. Myriad also carries a Zacks Rank #2 (Buy). 

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UNITED THER… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%